Auxilium sues Watson on testosterone gel patent

Thu May 24, 2012 6:11pm IST

Related Topics

Stocks

   

(Reuters) - Auxilium Pharmaceuticals Inc sued Watson Pharmaceuticals Inc alleging that it infringed patents related to Auxilium's testosterone gel Testim.

A unit of Watson had filed with U.S. health regulators last month for the approval of a generic version of Testim.

As a result of the lawsuit, regulatory approval of Watson's generic version will be stayed for 30 months, or until the litigation is resolved, Auxilium said.

In its suit, Auxilium alleged that Watson's gel infringed ten patents that are expected to expire between 2023 and 2025.

Auxilium had entered into a co-promotion agreement with a unit of GlaxoSmithKline on Monday to jointly sell Testim.

Shares of Auxilium, which have risen 10 percent since the company entered into the GlaxoSmithKline agreement, closed at $19.23 on Wednesday on the Nasdaq. Watson shares were at $70.71 at close on the New York Stock Exchange on Wednesday.

(Reporting by Adithya Venkatesan in Bangalore; Editing by Sreejiraj Eluvangal)

FILED UNDER:
  • Most Popular
  • Most Shared
Biotech Leap

Biotech Leap

World's top drugmaker Novartis takes aim at tech  Full Article 

Bird Flu

Bird Flu

Bird flu found in UK, Netherlands but authorities say little risk to humans  Full Article 

Drug Abuse

Drug Abuse

‘Tweens’ most likely to misuse over-the-counter meds.  Full Article 

Nutrition Value

Nutrition Value

School lunches may be better than lunch packed at home.  Full Article 

Smoking Problem

Smoking Problem

U.S. youth smoking, increased use of e-cigarettes a worry: CDC.  Full Article 

No Progress

No Progress

Progress on eliminating measles has stalled, WHO warns.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage